Zeta Potential Analyzers Market Size, Share, and Industry Analysis, By Product Type (Electrophoretic Light Scattering (ELS), Acoustic Zeta Potential Analyzers, and Others), By End-user (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Others), and Regional Forecast, 2026-2034

The zeta potential analyzers market size was valued at USD 105.5 million in 2025 and is expected to reach a market valuation of USD 112.7 million in 2026. Furthermore, the market is projected to reach a market valuation of USD 191.2 million by 2034, exhibiting a CAGR of 6.8% during the forecast period.

The market is witnessing significant growth, driven by a stronger emphasis on formulation stability and quality characterization in pharma and biotech, which is expected to fuel demand for zeta potential analyzers in the coming years.

Zeta Potential Analyzers Market Driver

Rising Development of Nanomedicines, Lipid Nanoparticles, and Biologic Drug Products to Drive the Market Growth

Over the past few years, there has been increasing development of nanomedicines, lipid nanoparticles, and biologic drug products, which are being approved by regulatory authorities. This directly supports demand for zeta potential analyzers, as these tools are used to assess colloidal stability, surface charge behavior, and formulation robustness in drug development. Such a scenario is anticipated to hinder the market growth.

• For instance, as of March 2026, the FDA states that it has already reviewed and approved many nanotechnology-based products and expects increased use of nanoscale materials in medical products.

Download Free sample to learn more about this report.

According to data from the Cross River Therapy as of March 2026, there are more than 5,000 pharmaceutical companies in the U.S.

Zeta Potential Analyzers Market Restraint

Highly Sensitive Measurement Results to Hamper the Market Growth

Zeta potential is strongly influenced by pH, ionic strength, and the surrounding media. At higher ionic strengths, the electric double layer can collapse, making zeta values alone insufficient to judge stability. This is expected to limit straightforward interpretation in complex healthcare samples.

• For instance, in November 2023, ScienceDirect stated that higher ionic strength can cause the collapse of the electric double layer.

Zeta Potential Analyzers Market Opportunity

Growing Automation and Higher-throughput Workflows to Offer Lucrative Growth Opportunity

In recent years, automation has become more important as biopharma labs handle larger formulation screens and comparability studies. Also, the HPLC-enabled automation for zeta and size measurements is expected to offer significant opportunities for market expansion. Moreover, an increasing focus on low-volume, biologically relevant measurements is further driving this demand.

Segmentation

Key Insights

The report covers the following key insights:

• Advancements in Zeta Potential Analyzers
• Key Industry Developments - (Partnerships, Mergers, and Acquisitions, etc.)

Analysis by Product Type

By product type, the market is segmented into electrophoretic light scattering (ELS), acoustic zeta potential analyzers, and others.

The electrophoretic light scattering (ELS) segment is expected to hold the major share of the global market during the forecast period. The segment growth is attributed to their high accuracy, reproducibility, and suitability for nano-sized particles, which are widely used in biologics, liposomes, mRNA vaccines, and protein formulations.

Analysis by End-user

Based on end-user, the market is divided into pharmaceutical & biotechnology companies, academic & research institutes, and others.

The pharmaceutical & biotechnology companies segment is expected to hold the largest share of the global market during the forecast period. Pharmaceutical & biotechnology companies are the largest users, given zeta potential's critical role in drug formulation stability, biologic characterization, and regulatory compliance, which is expected to fuel the segment’s growth.

Regional Analysis

Request for Customization   to gain extensive market insights.

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for a 39.5% share of the global zeta potential analyzers market in 2025. The region has the strongest concentration of biopharma R&D, advanced drug formulation work, analytical testing infrastructure, and regulated quality-control environments, which is expected to augment the market growth.

Europe is expected to account for the second-largest market over the forecast period. The growth is fueled by an established regulatory framework for nanomedicines and the presence of prominent players in the region. Moreover, countries such as Germany, the U.K., France, and Switzerland combine instrument adoption with strong pharma and biotech research activity.

• For instance, as of March 2026, the European Medicines Agency has issued guidance on nanomedicines, and the European Commission’s research infrastructure includes nanobiotechnology laboratories that characterize particle size and zeta potential for nanomedicines and biomaterials.

Key Players Covered

The global zeta potential analyzers market is moderately consolidated, with key players focused on continuous product innovation and expansion in biopharma & nanomedicine applications.

The report includes the profiles of the following key players:

• Securitas Healthcare LLC (U.S.)
• HID Global Corporation (U.S.)
• CenTrak, Inc. (U.S.)
• RF Technologies (RFT) (U.S.)
• Accutech (U.S.)
• Secure Care Systems (U.S.)
• Litum (Turkey)
• Ascom (Switzerland)
• McRoberts Technologies (Netherlands)
• Cornell Communications (U.S.)

Key Industry Developments

• April 2024: Malvern Panalytical launched the Zetasizer Sample Assistant, an automated accessory for its Zetasizer Advance light-scattering instruments, enabling round-the-clock particle size, zeta potential, and concentration measurements with minimal supervision.
• October 2023: L.N. Gumilyov Eurasian National University acquired a modern NanoBrook ZetaPALS zeta potential analyzer.